Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 18/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 18/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 18/20 | 1.00 |
| ▸ | TNF | P01375 | 4/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977548 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637197 | 0.89 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL1193568 | 0.88 | PDE4B (0.77) | PDE4APDE4BPDE4CPDE4DHTR2B | |
| SCHEMBL9977546 | 0.87 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL23509448 | 0.86 | PDE4B (0.75) | PDE4APDE4BPDE4CPDE4DHTR2B | |
| SCHEMBL7440313 | 0.85 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL7432884 | 0.85 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DTNF | |
| Cdc-801 SCHEMBL185853 | 0.84 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637167 | 0.84 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL9977581 | 0.84 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | claimed |
| US-8263637-B2 | Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012083153-A1 | OLIGOMER-CONTAINING APREMILAST MOIETY COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20110038832-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | CELGENE CORPORATION | 2011-02-17 | — | — | US | disclosed |
| EP-2258363-A1 | Compositions for treatment of cancers | CELGENE CORPORATION (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7842691-B2 | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2010-11-30 | — | — | US | disclosed |
| US-7776907-B2 | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide | CELGENE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1587474-B1 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1569903-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2004034962-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086373-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | disclosed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-6011050-A | Substituted phenethylsulfones and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
| US-6011050-A | Substituted phenethylsulfones and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | IL2, HDGF, VEGFA | PDE4A 1843/4885PDE4B 1724/4885PDE4C 1641/4885 |
| US-20110038832-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | ALDH1A2, MTNR1A, MTNR1B | PDE4A 243/4885PDE4B 438/4885PDE4C 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.